Determination of KRAS- and ERK-regulated phosphoproteomes in KRAS-mutant cancers

被引：0

作者：

Klomp, Jennifer E. ^{[1
]}

Klomp, Jeff A. ^{[1
]}

Diehl, Nathaniel J. ^{[1
]}

Edwards, Cole A. ^{[1
]}

Drizyte-Miller, Kristina ^{[1
]}

Hibshman, Priya S. ^{[1
]}

Yang, Runying ^{[1
]}

Morales, Alexis J. ^{[1
]}

Taylor, Khalilah E. ^{[1
]}

Pierobon, Mariaelena ^{[2
]}

Petricoin, Emanuel F., III ^{[2
]}

Jared, Johnson L. ^{[3
]}

Huntsman, Emily M. ^{[3
]}

Yaron, Tomer M. ^{[4
]}

Vaha-Koskela, Markus ^{[5
]}

Herring, Laura E. ^{[1
]}

Prevatte, Alex W. ^{[1
]}

Barker, Natalie K. ^{[1
]}

Graves, Lee M. ^{[1
]}

Krister, Wennerberg ^{[5
]}

Cantley, Lewis C. ^{[3
]}

Christensen, James G. ^{[6
]}

Cox, Adrienne D. ^{[1
]}

Der, Channing J. ^{[1
]}

Stalnecker, Clint A. ^{[1
]}

机构：

[1] Univ N Carolina, Chapel Hill, NC USA

[2] George Mason Univ, Fairfax, VA USA

[3] Weill Cornell Med, New York, NY USA

[4] Columbia Univ, Vagelos Coll Physicians & Surg, New York, NY USA

[5] Univ Copenhagen, Copenhagen, Denmark

[6] Mirati Therapeut, San Diego, CA USA

来源：

MOLECULAR CANCER RESEARCH | 2023年 / 21卷 / 05期

关键词：

D O I：

10.1158/1557-3125.RAS23-B034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B034

引用

页数：2

共 50 条

[21] ERK MAPK inhibition enhances the immunogenicity of KRAS-mutant colorectal cancer.
Ryan, Meagan B.
de la Cruz, Ferran Fece
Ahronian, Leanne G.
Phat, Sarah
Myers, David T.
Shahzade, Heather A.
Hong, Catriona
Corcoran, Ryan B.
MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 76 - 76
[22] Novel Polymethoxylated Chalcones as Potential Compounds Against KRAS-Mutant Colorectal Cancers
Mahmoud, Alaa
Elkhalifa, Dana
Alali, Feras
Al Moustafa, Ala-Eddin
Khalil, Ashraf
CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (14) : 1622 - 1633
[23] SPECIFIC KRAS-MUTANT CANCERS ARE SENSITIVE TO INHIBITION OF V-TYPE ATPases
不详
CANCER DISCOVERY, 2022, 12 (10) : 2229 - 2229
[24] Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Adachi, Yuta
Kimura, Ryo
Hirade, Kentaro
Ebi, Hiromichi
CANCERS, 2021, 13 (20)
[25] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Xiufeng Pang
Mingyao Liu
Chinese Journal of Cancer, 2016, 35 (11) : 571 - 573
[26] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Pang, Xiufeng
Liu, Mingyao
CHINESE JOURNAL OF CANCER, 2016, 35 : 92
[27] Role of silent mutations in KRAS-mutant tumors
Lu Jun
Zhou Chao
Pan Feng
Liu Hongyu
Jiang Haohua
Zhong Hua
Han Baohui
中华医学杂志英文版, 2025, 138 (03)
[28] Closing the door on KRAS-mutant lung cancer
Cully, Megan
NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (11) : 747 - 747
[29] Osteopontin drives KRAS-mutant lung adenocarcinoma
Giopanou, Ioanna
Kanellakis, Nikolaos, I
Giannou, Anastasios D.
Lilis, Ioannis
Marazioti, Antonia
Spella, Magda
Papaleonidopoulos, Vassilios
Simoes, Davina C. M.
Zazara, Dimitra E.
Agalioti, Theodora
Moschos, Charalampos
Magkouta, Sophia
Kalomenidis, Ioannis
Panoutsakopoulou, Vily
Lamort, Anne-Sophie
Stathopoulos, Georgios T.
Psallidas, Ioannis
CARCINOGENESIS, 2020, 41 (08) : 1134 - 1144
[30] Closing the door on KRAS-mutant lung cancer
Megan Cully
Nature Reviews Drug Discovery, 2016, 15 : 747 - 747

← 1 2 3 4 5 →